GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Quick Ratio

Ra Pharmaceuticals (Ra Pharmaceuticals) Quick Ratio : 14.79 (As of Dec. 2019)


View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Ra Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2019 was 14.79.

Ra Pharmaceuticals has a quick ratio of 14.79. It generally indicates good short-term financial strength.

The historical rank and industry rank for Ra Pharmaceuticals's Quick Ratio or its related term are showing as below:

RARX's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.49
* Ranked among companies with meaningful Quick Ratio only.

Ra Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Ra Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Quick Ratio Chart

Ra Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Quick Ratio
Get a 7-Day Free Trial 2.91 17.74 8.46 20.82 14.79

Ra Pharmaceuticals Quarterly Data
Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.82 20.10 15.30 25.73 14.79

Competitive Comparison of Ra Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Ra Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ra Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's Quick Ratio falls into.



Ra Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Ra Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(274.694-0)/18.579
=14.79

Ra Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2019 is calculated as

Quick Ratio (Q: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(274.694-0)/18.579
=14.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ra Pharmaceuticals  (NAS:RARX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Ra Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
87 Cambridge Park Drive, Cambridge, MA, USA, 02140
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.
Executives
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco director, officer: President and CEO 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins 10 percent owner
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner officer: Executive VP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Ra Pharmaceuticals (Ra Pharmaceuticals) Headlines

From GuruFocus

4 Stocks With More Than 20% Price Increases on Thursday

By James Li James Li 10-10-2019